AngioDynamics vs InfuSystem
ANGO and INFU side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANGO and INFU compare
AngioDynamics is the larger company, worth 1.7 times as much as InfuSystem ($522M against $300M).
AngioDynamics grew revenue faster over the last twelve months (8.2% versus 2.4% for InfuSystem).
InfuSystem keeps more of each dollar of sales as profit, with a net margin of 6.5% compared with −10.1% at AngioDynamics.
InfuSystem scores higher on the StockData Score (15 against 12 for AngioDynamics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANGO | INFU |
|---|---|---|
| Size and price | ||
| Market cap | $522M | $300M |
| Share price | $12.42 | $15.08 |
| Change, 1 year | 1.1% | 49.5% |
| Change, 5 years | −56.5% | −15.6% |
| Beta (5Y) | 0.34 | 1.19 |
| Employees | 632 | 473 |
| StockData Score | ||
| Total score | 12 | 15 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 3 | 4 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 33.5× |
| P/S | 1.6× (better) | 2.1× |
| P/B | 3.2× (better) | 4.7× |
| EV/EBITDA | – | 11.5× |
| P/FCF | 362× | 12.1× (better) |
| FCF yield | 0.28% | 8.2% (better) |
| Fair value | $13.24 | $15.43 |
| Margin of safety | 6.2% (better) | 2.3% |
| Growth | ||
| Revenue growth (TTM) | 8.2% (better) | 2.4% |
| Revenue growth, 5Y average | 1.9% | 8.1% (better) |
| Net income growth (TTM) | – | 70.9% |
| EPS growth (TTM) | – | 73.1% |
| EPS growth, 5Y average | – | −17.3% |
| Profitability | ||
| Gross margin | 55.7% | 57.6% (better) |
| Operating margin | −11.2% | 9.8% (better) |
| Net margin | −10.1% | 6.5% (better) |
| FCF margin | 0.44% | 17.1% (better) |
| Return on equity | −19.2% | 15.8% (better) |
| Return on invested capital | −21.4% | 13.4% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.31 (better) |
| Net debt / EBITDA | – | 0.39 |
| Interest coverage | – | 13.8× |
| Current ratio | 2.40 | 2.68 (better) |
| Altman Z-score | 2.54 | 5.86 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 2.1% |
| Shareholder yield | 0.00% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 91.0% | 79.1% |
| Held by insiders | 5.8% | 12.2% |
| Insider net buying, 12 months | −$655K | $150K (better) |
| Short interest, % of float | 5.1% | 3.9% |
Go deeper
- ANGO stock overview
- ANGO income statement
- ANGO valuation and score
- INFU stock overview
- INFU income statement
- INFU valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.